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Abbreviations 
%: percent 
°C: degree Celsius 
µl: microliter  
µm: micrometer 
ACE-I: Angiotensin converting enzyme inhibitor 
ACS: Acute Coronary Syndrome 
ADP: Adenosine diphosphate 
AFib: Atrial fibrillation 
AP: Angina Pectoris 
Aqua dest.: Aqua destillata 
ARB: Angiotensin receptor blocker 
ASA: Acetylsalicylic acid 
BMI: Body mass index 
BMP: Bone Morphogenetic Protein 
BP: Blood pressure  
Ca2+: Calcium  
CAD: Coronary artery disease 
CD: Cluster of differentiation 
CHD: Coronary heart disease 
CK: Creatine kinase  
COPD: Chronic obstructive pulmonary disease  
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COX-1: Cyclooxygenase - 1 
CRP: C-reactive protein 
CVD: Cardiovascular disease 
CVP: Central venous pressure  
DAB: Diaminobenzidine 
DAPT: dual antiplatelet therapy  
dl: deciliters 
DM II: Diabetes Mellitus Type 2  
DNA: Deoxyribonucleic acid 
ECG: Electrocardiogram 
EF: Ejection fraction 
ESC: European Society of Cardiology 
f.ex.: for example 
FBS: Fetal bovine serum 
FCS: Fetal calf serum 
Fig.: Figure 
g: gram 
GFR-MDRD: Glomerular filtration rate-modification of diet in renal disease 
equation 
GP: Glycoprotein 
H/DIC: H/ Differential interference contrast 
H2O2: Hydrogen peroxide 
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Hb: Hemoglobin  
HbA1c: HemoglobinA1c  
HDL: High-density lipoprotein  
HE-Stain: Hematoxylin and Eosin stain 
HIER: Heat induced epitope retrieval  
Hrs: Hours  
i.e.: id est  
IAP: Instable Angina Pectoris 
IgG: Immunoglobulin G 
IHD: Ischemic heart disease 
kg: kilogram 
LD: Loading dose 
LDH: Lactate dehydrogenase  
LDL: Low-density lipoprotein  
LPS: Lipopolysaccharide  
LVEF: Left ventricular ejection fraction 
m2: square meters 
mg: Milligram 
MI: Myocardial Infarction 
MIF: Macrophage Migration Inhibitory Factor 
Min (s): Minute (s) 
ml: Milliliter 
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mmHg: Millimeter of mercury  
MPO: Myeloperoxidase 
MRA: Mineralocorticoid receptor antagonist  
NOAC: Novel oral anticoagulant(s) 
NSTEMI: Non-ST-Segment-Elevation Myocardial Infarction 
NYHA: New York Heart Association  
OAC: oral anticoagulant(s) 
PAD: Peripheral arterial disease  
PAP: Peroxidase- anti-peroxidase 
PAP: pulmonary artery pressure  
PBS: Phosphate-buffered saline 
PCI: Percutaneous Coronary Intervention 
PE: Phycoerythrin 
PIER: Proteolytic-induced epitope retrieval 
PPI: Proton-pump inhibitor  
RNA: Ribonucleic acid 
rpm: Rounds per minute 
s.: see 
SAB: Streptavidin-Biotin 
SCD: Sudden cardiac death 
SD: Standard deviation 
sec: Second(s) 
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SGOT: Serum glutamic oxaloacetic transaminase  
STEMI: ST-Segment-Elevation Myocardial Infarction 
TGFß: Transforming Growth Factor beta 
TLR: Toll-Like receptor   
TnI: troponin I 
U: units 
vWF: von Willebrand factor 
WHO: World Health Organization 
y: years 
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1. Introduction 
During the past two decades Cardiovascular Disease (CVD) has evolved into 
the leading cause of death worldwide.[1] 
According to the World Health Organization WHO it accounted for over 17 
million deaths in 2015, 8.76 million of which were due to Ischemic Heart 
Disease (IHD), followed by strokes with 6.24 million. The total amount 
represents a percentage of 31 of all deaths worldwide.[2] 
 
1.1. Coronary Artery Disease 
The medical entity Ischemic Heart Disease (IHD) or Coronary Artery Disease 
(CAD) comprises a group of cardiac conditions including Angina Pectoris 
(stable and instable), Myocardial Infarction (STEMI and NSTEMI) as well as 
Sudden Cardiac Death (SCD).[1,3] 
Ischemia signifies insufficient blood supply to tissues (partial or total), resulting 
in lack of oxygen, consecutive disturbance of cell metabolism and cell damage 
and thus dysfunction of the tissue and organ. Restriction in blood supply can 
have several reasons such as vasoconstriction, thrombosis or embolism, in IHD 
it is primarily the result of atherosclerosis of the coronary arteries.[4-6] 
Atherosclerosis, a condition describing the hardening and narrowing of arteries, 
occurs due to plaque build-up in the artery walls and progresses over a long 
period of time. The mechanisms of plaque formation are not entirely 
understood, although it is known that plaques are generally lipid-rich.[6] Acute 
plaque rupture can lead to thrombosis and total occlusion of the vessel. The 
Framingham Study established a variety of risk factors for CAD [7] most of which 
are congruent with the risk factors for atherosclerosis.  These are still in clinical 
practice and are part of the baseline patient characteristics involved in this 
study. 
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Clinically CAD may present itself as either a chronic condition, which includes 
stable CAD or as an Acute Coronary Syndrome (ACS). The latter is further 
subcategorized in IAP, NSTEMI and STEMI.[3] 
1.1.1. Stable Coronary Artery Disease (CAD) 
Angina Pectoris derives from the Latin words “angere” and “pectus” [8] and 
describes the classical symptom- chest pain in form of a strangling feeling 
usually in the center of the chest.[9] Pain or discomfort may also occur or project 
into the jaw, arms, back or neck, in less frequent cases into the epigastrium. 
Those symptoms are signs of myocardial ischemia and are usually a 
manifestation of atherosclerosis in the coronary vessels.[10] Two 
pathophysiological factors play a main role in causing ischemia. For one, due to 
atherosclerosis the diameter of the vessels is reduced to such an extent that 
blood perfusion and therefore oxygen supply to the myocardium does not meet 
the metabolic demands of the heart muscle anymore.[11]  The second factor is 
the hardening of the artery walls leading to a loss in elasticity.[12] In case of 
increased demands the human blood vessels physiologically expand to 
increase blood perfusion and to provide higher amounts of oxygen to the 
recipient organs by doing so. Hence loss of elasticity of the arteries’ walls 
signifies less adaptive, dysfunctional vessels.  
In stable CAD symptoms generally occur if oxygen consumption exceeds the 
supply due to increased physical activity or stress.  At rest blood perfusion 
through the narrowed arteries might still be sufficient for the heart muscle to 
function normally. This explains why generally an artery obstruction of up to 
75% remains without symptoms. In case of increased metabolic demands the 
second pathomechanism described above comes into play. In stable CAD 
terminating physical activity or administration of nitroglycerin as vasodilating 
agent usually leads to an abatement of the typical symptoms and recurrence 
thereof as soon as physical activity resumes. 
1.1.2. Acute Coronary Syndrome (ACS) 
ACS is a potentially lethal manifestation of CAD.  ACS embraces the following 
subcategories: 
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1.1.2.1. Instable Angina Pectoris (IAP)  
As opposed to stable CAD in IAP symptoms may also occur at rest.  
Nitroglycerin might have lost its palliating effect since the disease is too far 
progressed. Instable Angina Pectoris can be regarded as an indicator of an 
imminent myocardial infarction.  Additionally every de-novo angina is by 
definition considered an IAP.[3] 
1.1.2.2. Non-ST-elevation-Myocardial Infarction (NSTEMI) 
A Non-ST-Elevation-Myocardial Infarction signifies ischemia of the myocardium 
resulting in loss of functional heart muscle tissue. This is indicated by elevated 
heart enzyme levels, i.e. Troponin, in lab results. The electrocardiogram might 
show signs of an acute heart attack such as ST-Segment depression, 
arrhythmias, ventricular extrasystole etc. but never an ST-Segment elevation as 
also implied in the name. 
1.1.2.3. ST-Elevation Myocardial Infarction (STEMI) 
An ST-Elevation Myocardial Infarction describes a type of severe myocardial 
ischemia that often results in significant tissue damage. The resulting loss of 
function and disturbed electrical repolarization show as elevated ST-segments 
in the ECG or as first diagnosed left bundle branch block. Troponin levels will 
also be elevated. The severity of the condition and coherent technical findings 
express a usually total occlusion of the coronary artery through thrombosis, 
either due to plaque rupture or thromboembolism. The tissue damage in this 
case is usually transmural, meaning it affects all layers of the myocardium wall 
as opposed to NSTEMI where only the most inward layer, which is naturally the 
one furthest away from blood and oxygen supply, is affected. 
Hence a main cause for acute myocardial infarction, STEMI in particular, in 
patients with coronary artery disease is the formation of intracoronary thrombi. 
The impact of thrombus formation on size of infarction, reperfusion injury as well 
as clinical outcome and thus prognosis for the patient varies. It is determined by 
the morphological structure, composition and differentiation of intracoronary 
thrombi. Therefore these are subject to different pharmacological and invasive 
treatment strategies and form the investigative background of this research.   
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1.2. Thrombus formation 
In the mid 19th century the German pathologist Rudolf Virchow described the 
causal factors that according to his findings lead to thrombosis.[13, 14] Although 
he referred to phlebothrombosis, a thrombosis of the veins, at the core the 
same factors are causal for arterial thrombosis. They became to be known as 
Virchow’s triad. These are: 
1. Endothelial damage or alterations: damage or alterations of the inner 
vessel wall leads to inflammatory processes, attracting platelets and 
other inflammatory cells to the site of injury. As a natural mechanism and 
as part of the healing process these cells will clot. Additionally, the 
damage and/or the resulting clot may lead to a change in blood flow, 
which is the second causal factor for thrombosis according to Virchow. 
2. Hemodynamic changes/Alterations of blood flow velocity: In the venous 
system this is usually due to speed decrease which is known as stasis. 
This makes it easier for blood particles to pile up and stick to the vessel 
walls. In the arterial system thrombosis preferably develops where 
turbulences occur. This is either the case at division sites within the 
arterial tree, where larger arteries branch out into smaller ones or at sites 
of damage as described in the aforementioned 1. 
3. Changes in blood viscosity/Hypercoagulability: Virchow found that the 
thicker the blood the more likely it is to clot. The reason for a higher 
viscosity can either be obtained, f.ex. through exsiccosis or 
thrombocytosis or genetic f.ex. due to deficiency of protein C/S or 
antithrombin III.[13] 
Although there are differences in venous and arterial thrombosis, the above 
factors also apply for the arterial system, the two former ones in particular. In 
acute myocardial infarction a thrombus forms either as a result of 
atherosclerotic plaque rupture that leads to endothelial damage and exposes 
thrombogenic substances that were previously covered by a thin fibrous cap to 
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the blood stream.[11] Less frequently, arterial thrombi also form at so-called 
plaque erosion sites that combine endothelial lesions with thickening of the 
intima.[11] In the case of disrupted atherosclerotic plaque rupture the now 
exposed material triggers natural hemostasis, including platelet adhesion, 
aggregation and activation and the formation of a fibrin mesh, together forming 
a thrombus that may lead to transient or persistent occlusion of the vessel. 
Although both, arterial and venous thrombi contain platelets and fibrin, arterial 
thrombi are typically platelet-rich due to the high shear conditions under which 
they form, whereas the fibrin content of venous thrombi is higher and the 
platelet count low.[1] 
1.2.1. Role of platelets 
Platelets stem from megacaryocytes.[15] They are anucleate cells and have an 
approximate life span of 7-10 days. They circulate in the blood stream and play 
an important role in primary hemostasis and thrombus formation.[16] Injury to the 
endothelium leads to exposure of von Willebrand factor (vWF) and 
subendothelial collagen to which platelets adhere via their surface receptors GP 
Iα and GP IIb/IIIa for vWF and α2ß1 as well as GP IV for collagen.[17-20]. The GP 
IIb/IIIa not only plays an important role in primary adhesion and activation, but 
also in sustained platelet aggregation and thrombus stabilization. It is 
particularly susceptible for vWF under high shear conditions. [21] Another 
receptor ligand is fibrinogen. Both ligands amplify the induced signaling and 
activation pathway as part of a positive feedback mechanism.[20]   
Following adhesion, platelets become activated and release ADP from 
intracellular granules in addition to Thromboxane A2, which is synthesized by 
their intrinsic cyclooxygenase-1 (COX-1).  Both substances amplify the 
signaling pathway even further by recruiting more platelets to the site of lesion 
and activating them. Thromboxane A2 also functions as vasoconstrictor.[20, 22]   
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Fig. 1 taken from Halkar M, Lincoff AM, Dual antiplatelet therapy for acute coronary 
syndromes: How long to continue? Clinic Cleveland Journal of Medicine, 2016 [23] 
In order to effectively activate further platelets ADP binds to the platelets 
membrane receptors P2Y12 and P2Y1 and Thromboxane A2 to its TP receptor 
that is found on platelets as well as on endothelial cells. Increased intracellular 
calcium levels after receptor activation lead to conformational change of the 
platelets cytoskeleton and mobilization and release of further granules, thus 
amplifying aggregation and activation.[24-27]  
.
Resting platelets       Activated Platelets 
Fig.2 Credit: Department of Pathology College of Veterinary Medicine the University of 
Georgia Athens [28] 
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Furthermore, activated platelets support the coagulation system not only by 
releasing factors V, XI, XIII and fibrinogen but also by providing coagulatory 
factors with anionic surface phospholipids which are required for the intrinsic 
pathway of the coagulation cascade as a binding site. The coagulation cascade 
ultimately leads to formation of thrombin and consequently to fibrin. In the sense 
of a positive feedback loop thrombin also amplifies platelet attraction and 
activation, thus supporting the growth of the platelet-fibrin thrombus.[29, 30]  
 
 
Fig. 3 taken and modified from Xu XR, Zhang D, Oswald BE, Carrim N, Wang X, Hou Y 
et al., Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune 
responses, tumor metastasis and beyond. [31] 
Fibrin is rendered into its active form by thrombin which cleaves fibrinogen, a 
soluble plasma protein, to build fibrin monomers. These insoluble monomers 
interlink and form fibrin strands that are stabilized by factor XIII. The resulting 
16 
 
fibrin mesh helps anchoring the platelets and so stabilizes the platelet plug.[1, 32- 
33] 
 
Fig. 4: Three-dimensional platelet-fibrin mesh formed on collagen under high shear 
conditions. Credit: Perelman School of Medicine, University of Pennsylvania 
1.2.2. Intracoronary thrombi 
Intracoronary thrombi that cause acute vessel obstruction or in-stent thrombosis 
consist of platelets, inflammatory cells such as monocytes, macrophages and 
neutrophils and other blood cells like fibroblasts. Previous studies have shown a 
high variability in thrombus composition in terms of the relative amounts of 
different cell types and fibrin content.[34]  
The underlying pathophysiological processes of cell aggregation and 
interaction, thrombus formation and differentiation and the influencing factors of 
these processes in acute myocardial infarction are not yet fully understood.[35] 
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1.3. Antiplatelet therapies 
The current clinical concept of preventing and treating coronary thrombosis is 
based on a dual antiaggregatory therapy. The common drug combination in 
clinical use is ASA plus a drug of the thienopyridine group, such as Clopidogrel, 
Ticlopidine or Prasugrel.  
1.3.1. Aspirin 
The standard antiplatelet drug is ASA, which inhibits the platelets’ intrinsic 
enzyme COX-1 irreversibly. The result is a decrease in Thromboxane A2 
synthesis and secretion, thus disrupting the pathway of an amplified adhesion 
and activation of platelets as well as preventing vasoconstriction. 
1.3.2. Clopidogrel, Prasugrel, Ticlopidine 
Those drugs target the platelets’ P2Y12 receptor, inhibiting it irreversibly and 
thus preventing ADP-mediated platelet activation and recruitment. Drugs of the 
thienopyridine group are pro-drugs and need to be metabolically activated. 
Alternatives are non-thienopyridine derivatives such as Ticagrelor or Cangrelor. 
Since they are not pro-drugs there is no need for metabolic activation.  Another 
difference to the thienopyridine group is that receptor-inhibition is reversible. 
This study focuses on the two main drugs of the thienopyridine-group 
Clopidogrel and Prasugrel.  
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Fig. 5 taken and modified from Braunwald's Heart Disease: A Textbook of 
Cardiovascular Medicine, 10th ed. 2015 [1]: Antiplatelet drugs and their sites of action  
There are preliminary studies suggesting that Prasugrel reduces thrombus size 
and formation.[36]  
Nevertheless the effects of the different antithrombotic premedication on 
thrombus composition and architecture remain unclear.  In particular, the 
specific antiplatelet regimens such as Prasugrel and Clopidogrel have not been 
compared yet in regard to their influence on thrombus architecture during or 
after acute myocardial infarction.  
 Clopidogrel Prasugrel 
Dose LD 600 mg, 75 mg/day LD 60 mg, 10 mg/day 
Receptor Inhibition Irreversible Irreversible 
Activation Prodrug Prodrug 
Onset of action 2-6 hrs 30 mins 
Duration of effect 3-10 days 7-10 days 
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Table 1: Main features of P2Y12 inhibitors of the Thienopyridine class, taken and 
modified from Eurasian Journal of Emergency Medicine [37] 
In comparison to Clopidogrel Prasugrel shows more stable pharmacokinetics 
and –dynamics, an overall more potent platelet inhibition and the most rapid 
onset of effect. It is therefore the antiplatelet drug of choice in acute ST-
elevation myocardial infarction.[38, 39] These beneficial characteristics of 
Prasugrel in comparison to Clopidogrel and their potential effects on the 
formation, differentiation and morphological structure of intracoronary thrombi in 
patients with acute ST-elevated myocardial infarction had not been investigated 
to date.  
 
1.4. Molecular Biomarkers 
The following molecular biomarkers were used in this study for 
immunohistochemical staining in order to analyze composition and 
differentiation of intracoronary thrombi. 
1.4.1. Cluster of differentiation 14 (CD14) 
CD14 is a protein expressed by monocytes, macrophages and to a lesser 
extent by neutrophils. It is known to function as a co-receptor to Toll-Like 
receptor 4 (TLR4) and therefore plays an important part in the immune defense 
of bacterial lipopolysaccharide (LPS) but also other molecular pathogens i.e. 
lipoteichoic acid.[40] In this study it was used to detect the inflammatory cells 
named above. 
1.4.2. Cluster of differentiation 42b (CD42b) 
CD42b is part of the Glycoprotein complex (GP) Ib/V/IX and is used by platelets 
to bind von Willebrand factor.[41] It is a platelets-specific surface marker. Hence 
it functioned as an immunohistochemical marker for platelet staining of 
thrombotic material obtained by aspiration during PCI. 
1.4.3. Cluster of differentiation 68 (CD68) 
CD68 is a glycoprotein primarily expressed by macrophages and other cells 
deriving from monocytes. It has been used as an immunohistochemical surface 
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marker to detect the presence of macrophages in intracoronary thrombi which is 
an indicator for an underlying inflammatory process.[42] 
1.4.4. Cluster of differentiation 105 (CD105) / Transforming Growth Factor beta 
(TGFß) 
CD105 is a cell surface glycoprotein and forms part of the TGFß receptor 
complex. It is also known as Endoglin. It appears to play an important part in 
angiogenesis, the development of new vessels from pre-existing ones as part of 
physiological healing processes and tissue granulation. Angiogenesis also 
occurs in tumor transformation and growth.[43] CD105 is furthermore expressed 
in monocytes and macrophages, as well as smooth muscle cells, particularly in 
vascular ones. The TGFß receptor complex is a cytokine that exists in 4 
different isoforms as part of the transforming growth factor superfamily.[44] When 
activated by a ligand, it will initiate transcriptions of genes that play a crucial role 
in regulating a variety of functions primarily of immune cells. These functions 
include cell differentiation and proliferation as well as chemotaxis and activation 
of immune cells. TGFß-1 is one of the isoforms that was first found in platelets 
and assumed to play an important role in physiological wound healing 
processes. Thus TGFß is a key indicator for inflammatory processes and 
responses.[44-46]  
1.4.5. Macrophage Migration Inhibitory Factor (MIF) 
MIF is an inflammatory cytokine that, as in vitro tests have shown, regulates 
monocyte adhesion and migration, regulates macrophage function and induces 
foam cell formation. Its function is pro-inflammatory.[47] As we have shown in 
previous clinical studies blood levels of MIF are significantly elevated in patients 
with symptomatic CAD.[48] 
1.4.6. Gremlin 1 (Grem1) 
Grem 1 is a protein that acts as inhibitor of BMPs, cytokines which are involved 
in multiple processes during embryonic development, inflammation and chronic 
fibrosis. It also acts as endogenous antagonist of MIF.[49] In patients with ACS 
and acute plaque rupture the Grem1/MIF ratio in blood plasma proved to be 
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significantly lower than in patients with stable CAD.[48] Whether MIF and Grem1 
are up-regulated in intracoronary thrombi was subject of this research study. 
1.4.8. H&E-Stain 
H&E stain can be seen as the gold standard in histological staining. It is 
supposed to give an overview of the constituents of a histological section, 
clearly distinguishing cell nuclei from extracellular proteins. It was therefore 
used to detect and quantify fibrin content and classify intracoronary thrombi 
according to their morphological structure. 
 
1.5. Aims 
The process of thrombus formation is complex and the influencing factors on 
thrombus composition and thus on its architecture are diverse. In this study we 
focused on the effects of different antithrombotic premedication such as 
Clopidogrel and Prasugrel on thrombus morphology in patients with acute or 
recent ST-segment elevation myocardial infarction.  
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2. Material and Methods 
For the analysis intracoronary thrombi of a total of 102 patients with acute (< 24 
hrs) or recent (24-72 hrs) ST-elevated-myocardial infarction were acquired from 
2 cardiological centers. The PCI and thrombectomy were performed at the 
University of Tübingen, Department of Cardiology, University Hospital of 
Tübingen and the Department of Cardiology, Klinik am Eichert Göppingen. 51 of 
the 102 patients were pretreated with 500 mg ASA plus Clopidogrel, the other 
half with 500 mg ASA plus Prasugrel either in the ambulance or on hospital 
admission. According to the common local clinical practice the Loading dose 
was 600 mg for Clopidogrel and 60 mg for Prasugrel. Except for the routine 
Heparin bolus no other antithrombotic loading was given.  
 
2.1. Patients’ baseline characteristics 
The gathered clinical data included patients’ baseline characteristics such as 
age at the time of the event, BMI, atrial fibrillation and additional relevant 
medication. Furthermore recorded were common cardiovascular risk factors 
such as tobacco use, hypercholesterinemia, hypertension, positive family 
history, diabetes and renal function. 
Transthoracic ultrasound gave an overview of the left ventricular ejection 
fraction. The PCI gave information to the degree of coronary artery disease. 
The study complies with the declaration of Helsinki and the guidelines of good 
clinical practice and was approved by the institutional ethics committee of the 
University of Tübingen. 
The following table 2 gives an overview of patients’ baseline characteristics, the 
statistical analysis and interpretation of the data will be found in the result 
section (section 3) of this paper: 
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Table 2: 
Parameters 
Clinical characteristics Further Clinical parameters 
Age, y Gender 
BMI [kg/m²] Previous MI 
BP systolic In-Stent thrombosis 
BP diastolic PAD 
Door-to-balloon time [mins] AFib 
PAP [mmHg] COPD 
Concomitant medication at study entry Biomarkers 
ASA Leukocytes [1/µl]  
Marcumar Hb [g/dl]  
Bivalirudin Platelets [1000/µl]  
Heparin 0-3hrs CRP [mg/dl] 
ß-blockers SGOT [U/l]  
ACE-I CK [U/l]  
ARB LDH [U/l]  
MRA TnI [µg/dl] 
Ca2+-Antagonist HbA1c [%]  
Statins Triglycerides [mg/dl] 
PPI Cholesterol [mg/dl] 
 LDL-Cholesterol [mg/dl] 
Cardiovascular Risk Factors HDL-Cholesterol [mg/dl] 
Hypertension Creatinine [mg/dl] 
Dyslipidemia GFR-MDRD [ml/min/1.73m2] 
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DM II 
 
Family History 
 
Smoker / ex 
 
LVEF Coronary Artery Disease 
>55% None 
50-54% 1 Vessel 
36-49% 2 Vessel 
<35% 3 Vessel 
ACE-I – angiotensin converting enzyme inhibitor, AFib – atrial fibrillation, ARB – angiotensin receptor 
blocker, ASA – acetylsalicylic acid, BMI – body mass index, BP – blood pressure, Ca2+ – Calcium, CK – 
creatine kinase, COPD – chronic obstructive pulmonary disease, CRP – C-reactive protein, DM II – 
Diabetes Mellitus Type 2, GFR-MDRD – glomerular filtration rate-modification of diet in renal disease 
equation, Hb – Hemoglobin, HbA1c – HemoglobinA1c, HDL – high-density lipoprotein, hrs – hours, kg – 
kilograms, LDH – lactate dehydrogenase, LDL – low-density lipoprotein, LVEF - left ventricular ejection 
fraction, m2 – square meters, MI – myocardial infarction, mins – minutes, mmHg – millimetre of mercury, 
MRA – mineralocorticoid receptor antagonist, NYHA – New York Heart Association, PAD – peripheral 
arterial disease, PAP – pulmonary artery pressure, PPI – proton-pump inhibitor, SGOT – serum glutamic 
oxaloacetic transaminase, TnI – troponin I, y – years.  
 
After retrieval of the thrombi the following study was done: 
 
2.2. Immunohistochemical Staining 
Parts of the obtained thrombus material were embedded in paraffin and cut into 
series of 5 µm thick sections on the microtome. For staining Gremlin 1, MIF, 
CD105, CD68, CD14, CD42b and TGFß were used. Additionally, H&E staining 
was produced to gain a general overview of the thrombus composition and the 
fibrin content. 
 
2.3. Material and Lab supplies 
2.3.1 Machines and Devices 
Scales     Denver Instrument   
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Floating bath     Medax Model Nr.: 25900 
Nikon Microscope    Nikon Optiphot-2  
Nikon Camera    Nikon Digital Sight DS-U1 
Microtome  Leica/Reichert-Jung Model 2045 
Multicut 
Clean bench     Thermo Electron Corporation HS18  
      40617682 
Exhaust/vent     Waldner Airflow Controller AC3 
Magnetic stirrer     IKAMAG®RET-GS 
Vortexer      IKA®MS 3 basic Ident-Nr. 0003617000 
Microwave     Severin Art.MW 7809 
pH – meter  HANNA instruments model nr.: AHI-
9124 
Timer Carl Roth GmbH+Co. KG model nr. TR118 
Water purification system Thermo Scientific TKA Genpure 
 
2.3.2. Solutions, agents 
Rotihistol      Roth Art.-Nr. 6640.1 
Roti-Histokitt      Roth Art.-Nr. 6638.2 
Paraplast Plus®     Roth Art.-Nr. X881.2 
Citric Acid      SIGMA-ALDRICH 251275 
Tri-Natrium-Dihydrate    AppliChem APA3901.1000 
Hydrogen peroxide 30%    EMSURE® 1072092500 
 Methanol      VWR Chemicals 20.847.307 
Ethanol 99%  UN 1170 SAV liquid production 
GmbH 
Tween®20 for synthesis     Merck Art.Nr. 8221840500 
Eosin G 50 mg     Roth Art.-Nr. 7089.1 
Mayers Hämalaun     Merck Art.-Nr. 1092490500  
L-Glutamine solution 200 mM    BioXtra Sigma-Aldrich G7513 
Paraformaldehyde     Merck Art.Nr. 8187151000 
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Acetic Acid (glacial) 100%    Merck Art.-Nr. 100063 
PBS Tablets      Gibco 1571002    
Liquid DAB + Substrate Chromogen System Dako K3468 
Streptavidin-HRP     Dako P0397 
Albumin Fraction V (pH 7.0)   AppliChem APA1391.0250 
 
2.3.3. Antibodies, Serum 
Primary antibody Secondary antibody 
CD 68 Santa Cruz SC 20060 Biotinylated link 
universal 
Dako K0690 
CD14 Biorbyt  orb19177  Biotinylated link 
universal 
Dako K0690 
CD42b Santa Cruz SC7070 
(discontinued)  
Biotinylated link 
universal  
Dako K0690 
CD105 Santa Cruz SC 20632 
(discontinued) 
Rabbit prediluted Abcam ab27422 
TGFß1 Santa Cruz SC146-G  Biotinylated link 
universal 
Dako K0690 
Grem1  Abnova PAB 14845 Rabbit polyclonal Dako X0936 
MIF R&D Systems AF-
289-PB  
Goat monoclonal Vector Laboratories 
I-5000 
Serum 
Anti-rabbit serum Dako X0909   
Anti-goat serum Dako E0466   
Table 3: Antibodies, Serum  
 
2.3.4. Lab supplies 
Pasteur pipette (sterile)    Ratiolab® Art.Nr. 2655135 
Scalpel (sterile)     Pfm medical Art.-Nr.: 200130023 
Falcon, 50ml, CELLSTAR®   Greiner bio-one Art.-Nr.: 227261 
Pipettes  Eppendorf 
Research®10;100;1000 
Pipette tips 200 µl     SARSTEDT 0109/5089011 
Ratiolab® Pipette tips Blue 1000 µl  Ratiolab Art.-Nr. 2100610 
Pipette tips, 10µl, colorless  Biozym Scientific GmbH Art.Nr. 
720011 
SuperFrost®Plus slides    R.Langenbrinck 03-0060  
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Cover slips 24x50 mm Stärke 0,13-0,16mm R.Langenbrinck 01-2450/1 
Cover slips 24x60mm Stärke 0,13-0,16mm R.Langenbrinck 01-2460/1 
Cover slips 24x40mm    Menzel-Gläser BB024040A1 
Duran®Laboratory bottles, 500ml, 1000ml  DURAN Group GmbH Art.Nr. 21 
801 44 59; 21 801 54 55 
Safe-Lock Tubes 0,5 ml    Eppendorf 0030 121.023 
Safe-Lock Tubes 1,5 ml    Eppendorf 0030 120.086 
Cellstar®Tubes 50 ml    Greiner bio-one Art.-Nr. 227261 
 
2.4. Methods 
2.4.1. H&E staining 
First the paraffin sections were deparaffinized and rehydrated in rotihistol and a 
graded alcohol series and then left in Aqua dest. for 5 minutes. Afterwards the 
sections were stained with a 1:5 hemalum solution (Aqua dest.1:5), blued for 15 
minutes under warm tap water and stained for 3 minutes with 1% Eosin. The 
sections were then washed again with distilled water and dehydrated in a 
graded alcohol series. Finally sections were mounted, covered with a cover slip 
using Rotihistol and left for overnight drying. 
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Fig. 6: Cell-rich thrombus in HE Stain 
 
 
Fig. 7: Thrombus rich in red blood cells in HE Stain 
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Fig. 8: Fibrotic/ amorphous thrombus in HE Stain 
 
 
Fig. 9: Thrombus of mixed morphology in HE Stain 
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Fig. 10-11: Platelet-rich thrombus in HE Stain 
2.4.2. Immunohistochemistry 
After deparaffinization and rehydration (s. HE staining) the slides were washed 
in PBS for 5 minutes and then boiled in citrate buffer (pH 6) for 2 minutes at 600 
Watts and consecutively for 3 minutes at 300 Watts. The heat treatment is used 
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to demask antigen epitopes. Formalin fixation and consecutive paraffin 
embedding leads to cross-linking of membrane proteins with formaldehyde 
molecules. The antigen epitopes are thus hardly accessible to primary 
antibodies and their binding is restricted. 
Through HIER (heat induced epitope retrieval) with a HIER-solution like citrate 
buffer or alternatively PIER (proteolytic-induced epitope retrieval, which uses a 
proteinase instead of heat) the mentioned cross-links will be dissolved and 
binding of primary antibodies to the relevant epitope is made possible. 
After short cooling time and repeated washings in Tween-PBS 0,05% the slides 
were put in 3% H2O2. This results in blocking of the endogenous peroxidase, in 
order to rule out false-positive signals later. After 15 minutes the sections were 
retransferred into Tween-PBS 0,05% and washed several times. The single 
objects of each series were then encircled with a Liquid-blocker PAP pen 
(Peroxidase- anti-Peroxidase) so that the convergence of different 
(prospectively used) agents (serum, antibodies etc.) was prevented. 
Afterwards a 5% serum was used for all objects, which was removed by tilting 
after 30 minutes. The serum is supposed to block unspecific bindings and 
should therefore be of the same kind of animal as the secondary antibody. As 
an unspecific serum was used, it is suited for blocking various secondary 
antibody types, such as mouse, goat, rat etc. 
Onto the first object of a three objects series an unconjugated primary antibody 
was applied; 30 µl were used per object. Object 2 served as IgG positive 
control, object 3 as PBS-negative control. 
After 1 hour of incubation the sections were washed repeatedly in 0,05% Tween 
PBS and then incubated for half an hour with a biotinylated secondary antibody. 
This method is based on the fact that biotin possesses 4 binding sites for Avidin 
and therefore the biotinylated antibody will be recognized easily by the SAB 
complex, rather the Avidin which was added in the following step. Additionally, 
Avidin is part of the same complex as the enzyme marker, the peroxidase, 
which will be consequently bound at the antigen at a higher number, and serves 
as signal amplification in the course of the process. 
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After another washing session with washing buffer, DAB-solution (1 ml of 
substrate buffer + 1 drop of stain) was added. The staining period varies 
between 2 to 10 minutes according to the speed in which brownish staining 
starts to occur. This is a critical part in the entire process, as there should be 
sufficient staining of the first object, but no staining of the IgG or PBS control. 
The brown stains develop through oxidation of the DAB solution which is linked 
to the SAB complex and H2O2 by the peroxidase. 
The slides were then washed again several times in 0,05% Tween PBS, the 
nuclei counterstained in 1:5 Hemalum for 3 minutes and consecutively blued for 
10 minutes under warm tap water. The following graded alcohol series 
 (5sec 70% Ethanol, 5 sec 80% Ethanol, 5sec 90% Ethanol, 2x 5mins 100% 
Ethanol and 3 mins Rotihistol, is employed for dehydration. Finally the slides 
were mounted and covered with Rotihistol and a glass cover slip and then left to 
dry for a period of 24 hrs. 
2.4.2.1. Immunohistochemistry- Photography 
The immunostained sections were photographed using a Nikon microscope with 
NJS Software. 4 fold, 10 fold and 20 fold magnification were used for each 
object. In order to establish an ideal contrast and suitable lighting conditions 
different filter strengths were employed, according to magnification level.  
The highest possible filter level (16+ 4+ 2) is needed for a 4 fold enlargement, 
for a 10 fold magnification, depending on the degree of staining, either the same 
or a 16+4 filter and for the highest degree of magnification the lowest filter 
combination of 16+ 2 was used. 
 
2.4.3. Statistical analysis 
Continuous variables are given as mean ± standard deviation (mean±-SD), 
when they were normally distributed. These variables were tested by two-sided 
t-test. Categorical data are presented as proportions and were analyzed by 
chi‐squared test. Continuous parameters were dichotomized at established 
cut‐off values. Values are given as mean ± standard deviation or standard error 
of the mean where applicable. Comparisons were considered statistically 
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significant if the two‐sided P value was ≤0.05. Statistical analyses were 
performed using SPSS software version 22.0 (SPSS Inc., Chicago, IL, USA).  
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3. Results 
The 102 patients of whom the thrombi were attained were either loaded with 
ASA and Prasugrel (n=51) or ASA and Clopidogrel (n=51) according to 
standard clinical practice. Loading took place either in the ambulance or on 
hospital admission.  
Additionally, the patients’ baseline characteristics were obtained and correlated 
to the immunohistological findings. The baseline characteristics are shown and 
evaluated below. 
 
3.1. Background and baseline characteristics  
Table 4: Clinical characteristics of patient population (n=102):  
Parameters 
Clopidogrel 
(n = 51) 
Prasugrel 
(n = 51) 
P 
Clinical characteristics 
Age, y 65.25 (±14.83) 57.52 (±10.84) 0.010 
BMI [kg/m²] 26.59 (±4.19) 27.88 (±4.70) 0.254 
BP systolic 126.14 ±20.05) 125.93 (±28.81) 0.986 
BP diastolic 70.00 (11.96) 72.67 (±12.16) 0.635 
Door-to-balloon  time 
[mins] 
1519,32 
(±3965,66) 
517,2 
(±1452,32) 
0.151 
PAP [mmHg] 26,50 (±6,79) 27,21 (±9,36) 0.822 
Values are given as mean ±SD. MI – body mass index, BP – blood pressure, kg – kilograms, m2 – square 
meters, mins – minutes, mmHg – millimetre of mercury, PAP – pulmonary artery pressure, y – years. 
The clinical characteristics of the patient population embraced standard 
parameters such as age, BMI and blood pressure measured in the ambulance 
or on hospital admission. As shown in table 4, there is a significant difference 
between the Clopidogrel and the Prasugrel group regarding the patients’ age. 
The Prasugrel cohort was with an average of 57.52 years younger than the 
Clopidogrel pretreated patients with an average age of 65.25 years. This is 
explained by current ESC guidelines that include certain aspects such as age 
and patients’ medical history in their recommendations. Based on these 
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guidelines Clopidogrel should be preferred over Prasugrel if there is a high risk 
for hemorrhage, like for example intracranial or gastrointestinal bleeding. As the 
risk for severe hemorrhage is elevated in older people Clopidogrel still is the 
drug of choice for patients above the age of 75 years as well as for patients with 
under 60 kg of body weight.  
Another aspect is the potential need for a so-called triple therapy or dual 
therapy with a NOAC as is the case in patients with atrial fibrillation undergoing 
PCI. Clopidogrel is still the only P2Y12 inhibitor that is recommended to be used 
in combination with any oral anticoagulant.[50] Taking into account that the 
prevalence of atrial fibrillation and therefore the necessity of a combinatory 
therapy with an oral anticoagulant increases with age, the difference between 
the two groups regarding that parameter is furthermore explained. 
The PAP and the LVEF (s. tables 5 and 8) were measured during PCI. Both 
parameters were within a close range to each other when comparing the results 
between the two groups. 
Another set of parameters that was analyzed and compared were the 
biomarkers obtained by blood samples listed in table 2. Blood samples were 
taken on hospital admission, labeled as “Day 0” and during the following days.   
The most relevant biomarkers for this study are summarized below. 
 
Table 5: Characteristics of patient population (n=102) - Biomarkers:  
Parameters 
Clopidogrel 
(n = 51) 
Prasugrel 
(n = 51) 
P 
Biomarkers 
Leukocytes Day 0 
[1/µl]  
14744,29 
(±5530,84) 
16920,67 
(±5562,51) 
0.402 
Hb Day 0 [g/dl]  12,57 (±1,84) 14,17 (±1,50) 0.042 
Platelets Day 0  
[1000/µl]  
238,92 (±91,08) 254,73 (±79,51) 0.461 
Platelets Day 1 
[1000/µl]  
218,42 (±70,53) 245,35 (±73,61) 0.186 
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CRP Day 0 [mg/dl] 3,06 (±4,56) 1,82 (±3,59) 0.225 
CRP Day 1 [mg/dl] 5,11 (±6,47) 7,22 (±14,91) 0.612 
CRP max [mg/dl] 9,04 (±8,87) 7,58 (±7,72) 0.701 
SGOT Day 0 [U/l]  278,24 (±278,56) 261,17(±333,90) 0.865 
SGOT Day 1 [U/l]  316,14 (±317,56) 201,50(±131,22) 0.408 
CK Day 0 [U/l]  1005,12(±1677,56) 1428,85(±2099,53) 0.376 
CK Day 1 [U/l]  1400,27(±1644,16) 1977,91(±1572,15) 0.196 
LDH Day 0 [U/l]  498,86(±391,79) 438,81(±410,42) 0.583 
LDH Day 1[U/l]  725,75(±434,83) 839,74(±405,78) 0.464 
TnI Day 0 [µg/dl] 99,16(±115,99) 127,27(±121,78) 0.510 
TnI max [µg/dl] 129,57(±123,48) 130,73(±119,61) 0.893 
HbA1c [%]  6,75(±0,9) 6,22(±1,10) 0.311 
Triglycerides [mg/dl] 135,85(±84,51) 119,41(±51,72) 0.563 
Cholesterol [mg/dl] 182,33(±50,78) 193,06(±42,2) 0.616 
LDL-Cholesterol 
[mg/dl] 
115,17(±43,82) 124,76(±31,5) 0.568 
HDL-Cholesterol 
[mg/dl] 
40,5(±8,69) 43(±14,67) 0.701 
Creatinine Day 0 
[mg/dl] 
1,07(±0,66) 1,12(±1,64) 0.906 
Creatinine Day 1 
[mg/dl] 
1,03(±0,60) 1,21(±1,82) 0.654 
GFR-MDRD Day 0 
[ml/min/1.73m2] 
80,93(±32,81) 87,93(±29,81) 0.387 
GFR-MDRD Day 1 
[ml/min/1.73m2] 
80(±38,98) 86,28(±28,70) 0.491 
Values are given as mean ±SD. CK – creative kinase, CRP – C-reactive protein, GFR-MDRD – glomerular 
filtration rate-modification of diet in renal disease equation, Hb – Hemoglobin, HbA1c – HemoglobinA1c, 
HDL – high-density lipoprotein, LDH – lactate dehydrogenase, LDL – low-density lipoprotein, SGOT – 
serum glutamic oxaloacetic transaminase, TnI – troponin I.  
 
As shown in table 5 there was a notable difference in Hemoglobin levels, which 
was with an average of 12,57 in the Clopidogrel group significantly lower than 
the Hb levels of the Prasugrel group with 14,17. This corresponds on one hand 
with the difference in age range, since Hemoglobin levels are often naturally 
lower in the older population. On the other hand, as mentioned above, a high 
risk for internal bleeding is a contraindication for Prasugrel administration. This 
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risk is usually determined by the patient’s medical history, which together with 
the lower Hb levels might be an indicator for more frequent bleeding incidences 
in the past in the Clopidogrel group, so that Prasugrel could not be administered 
in respect of current ESC guidelines. 
Leukocyte and CRP levels as marker for inflammatory processes did not differ 
significantly, neither did the platelets levels. However it has to be mentioned at 
this point that platelet cell count does not give any evidence about platelets’ 
function or activity. This marker was merely used to rule out any significant 
differences between the two groups that might have influenced the result of 
immunohistochemical staining and further statistical analysis. 
Further biomarkers were those indicating cell damage in general and 
myocardial cells in particular, such as troponin, creatine kinase (CK), lactate 
dehydrogenase (LDH), and serum glutamic oxaloacetic transaminase (SGOT). 
Although there was no significant difference between the two groups, the 
troponin levels in the Prasugrel group were initially distinctly higher, whereas 
the Clopidogrel group showed lower levels on admission, but reached nearly 
exactly the same maximum levels within the course of a few days as the 
Prasugrel group.  
Other cardiovascular risk markers such as HbAc1 as a diabetes marker or 
Triglycerides and Cholesterol levels as markers for dyslipidemia did not show 
any significant differences between the Clopidogrel and the Prasugrel arm. 
Nevertheless it has to be pointed out that the standard HbAc1 cut-off value for 
the diagnosis of Diabetes lies at 6.5%.  The Clopidogrel group showed a 
median value of 6.75%, while the Prasugrel group had an average level of 
6.22%. This signifies that the prevalence of Diabetes was more frequent in the 
Clopidogrel group than in the Prasugrel group. Both groups showed LDL-
cholesterol levels above the recommended values of 70-100 mg/dl, with the 
Prasugrel group leading slightly.  
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Renal function measured by creatinine levels and GFR did not differ 
significantly and stayed more or less stable after contrast medium exposure 
during PCI.  
The following table gives an overview of the patient baseline medication with 
main focus on drugs relevant for CAD treatment or treatment of related 
conditions.  
 
Table 6: Baseline characteristics of patient population (n=102) - Medication:  
Parameters 
Clopidogrel 
[%] 
Prasugrel 
[%] 
P 
(Chi square) 
Concomitant medication at study entry 
ASA 80  97,8  0.010 
Bivalirudin 48  34,1  0.264 
Heparin 0-3hrs 92,3  97,6  0.300 
ß-blockers 33,3  18,6  0.162 
ACE-I 25,9  23,3  0.800 
ARB 18,5  16,3  0.809 
MRA 14,3  6,7  0.563 
Ca2+-Antagonist 25,9  9,3  0.063 
Statins 25,9  18,6  0.467 
PPI 14,3  26,7  0.519 
Marcumar 11,1  2,3  0.123 
Values are given in [%] of group total. ACE-I – angiotensin converting enzyme inhibitor, ARB – angiotensin 
receptor blocker, ASA – acetylsalicylic acid, Ca2+ – Calcium, hrs – hours, MRA – mineralocorticoid 
receptor antagonist, PPI – proton-pump inhibitor. 
 
There is a significant difference between the two pretreatment groups regarding 
ASA as concomitant medication. In the Prasugrel group 97,8% used ASA as 
part of their long-term medication as opposed to merely 80% in the Clopidogrel 
group. The most conceivable reason for this significant difference is again, as 
mentioned above, the additional presence of other conditions such as atrial 
fibrillation that requires a different long-term strategy than a dual antiplatelet 
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therapy (DAPT). Another reason might be an intolerance or allergy to ASA with 
the simultaneous need for a life-long antiplatelet therapy. In this case patients 
are usually treated with Clopidogrel instead of ASA. Although not significantly, 
Phenprocoumon (Marcumar) use was slightly higher in the Clopidogrel group 
which further supports the additional-coagulant-theory, particularly since the use 
of other oral anticoagulants was not investigated upon. Regarding the common 
heart insufficiency/failure and CAD medication including ACE-Inhibitors, beta 
blockers, angiotensin receptor blockers and mineralocorticoid receptor 
antagonists there was again no significant difference between the two groups. 
Also other anticoagulants showed similar usage values for both pretreatment 
arms. Co-medication such as Ca2+-antagonists that are used to treat underlying 
causes for CAD, such as arterial hypertension and that are also known to have 
some antianginal effects, was clearly used more often by the Clopidogrel group, 
although the difference was not significant. 
 
Further clinical baseline characteristics of the patient population as well as the 
main cardiovascular risk factors and the type of CAD in terms of the number of 
vessels affected were obtained and are given in the table below in percentage 
for each group. 
 
Table 7: Further clinical baseline characteristics of patient population (n=102):  
Parameters 
Clopidogrel 
[%] 
Prasugrel 
[%] 
P 
(Chi square) 
Further Clinical parameters 
Male 71,9 82,6 0.259 
Previous MI 14,3  20  0.746 
In-Stent 
thrombosis 
12   4,9  0.289 
PAD 7,7  9,5  0.796 
AFib 32  4,8  0.002 
COPD 4,0  4,9  0.868 
Cardiovascular Risk Factors 
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Hypertension 65,4 63,6 0.883 
Dyslipidemia 42,3  45,5  0.798 
DM II 23,1  13,6  0.311 
Family History 11,5  27,3  0.144 
Smoker / ex 36  54,8  0.111 
LVEF 
Overall 
P 
>55% 28,6 12,0  
 
0,087 
50-54% 14 ,3 30 ,0 
36-49% 47,6 42 ,0 
<35% 9,5 16 ,0 
Coronary Artery Disease 
Overall 
P 
None 7,7  11,9   
 
0.302 
1 Vessel 42,3  21,4  
2 Vessel 15,4  26,2  
3 Vessel 34,6  40,5  
Values are given in [%] of group total.  AFib – atrial fibrillation, COPD – chronic obstructive pulmonary 
disease, DM II – Diabetes Mellitus Type 2, LVEF - left ventricular ejection fraction, MI – myocardial 
infarction, NYHA – New York Heart Association, PAD – peripheral arterial disease.  
As documented in the above table 7, the patients in both groups were 
predominantly male. An average of 18% of the study population had a 
myocardial infarction in the past, with no significant difference between the two 
groups, although the rate for previous MI was slightly elevated in the Prasugrel 
group. In-stent-thrombosis occurred in 12% of the Clopidogrel group and in 
nearly 5% of the Prasugrel group.   
There were approximately 1/3 of patients with atrial fibrillation in the Clopidogrel 
group in contrast to only 4.8 % in the Prasugrel group. This significant 
difference is explained by the fact that for patients in need of an OAC/NOAC in 
addition to an antiplatelet therapy Clopidgrel is the drug of choice.[50] The values 
for patients with peripheral arterial disease and chronic obstructive pulmonary 
disease did not differ considerably between the two groups.  
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In regard to cardiovascular risk factors the percentages for patients with 
hypertension and dyslipidemia were almost identical. Differences between the 
two groups regarding prediagnosed diabetes, family history for CAD or tobacco 
consumption were present but statistically not significant. There seems to be a 
higher prevalence of smokers and familial disposition in the Prasugrel group, 
whereas the prevalence of diabetes seemed to be higher in the Clopidogrel 
group. 
Left ventricular function was classified in 4 categories ranging from normal left 
ventricular function with an ejection fraction of >55% to mild (EF = 50-54%), 
moderate (EF = 36-49%) and severe left ventricular dysfunction with an EF 
<35%. In both groups the majority of patients had a moderate dysfunction. In 
the Clopidogrel group nearly 30% had a normal LVEF as opposed to the 
Prasugrel group where only 12% had a normal LVEF. 
In regard to the number of vessels affected in CAD patients, there were no 
significant differences between the Clopidogrel and the Prasugrel pretreated 
patients. No relevant CAD was present in 10% of the study population, which 
speaks for an acute thromboembolic event. In the Prasugrel group these 
accounted for 12%, in the Clopidogrel group for nearly 8%. In the Clopidgrel 
group a majority of 42% had 1-vessel-disease, in the Prasugrel group this 
occurred in only 21%. In the Prasugrel group in the majority of patients all 3 
vessels were affected (>40%) in the Clopidogrel group a 3-vessel disease was 
present in 34%.  
The primary aim for the collection of the data above was to rule out any 
statistically significant differences between the Clopidogrel and the Prasugrel 
group that might influence the results of immunohistochemical analysis. 
Although there were a few significant differences as mentioned above, these 
are partly the reason why one of the pretreatments was chosen over the other. 
It is therefore impossible to exclude these patients from a research study like 
this one. Overall the two medication groups did not show relevant and 
statistically significant differences so that a potential impact of patients’ baseline 
characteristics can be excluded. 
42 
 
3.2. Immunohistochemistry 
The aspirated thrombi were stained using the biomarkers CD14, CD42b, CD68, 
CD105, MIF, Grem1, TGFß and H&E staining for a general overview and to 
quantify the fibrin content. The results of the stainings were then analyzed 
comparing the Prasugrel with the Clopidogrel group. Interestingly, the 
immunohistochemical analysis showed a significant difference between the 
Clopidogrel and the Prasugrel group regarding the fibrin content. The obtained 
thrombotic material was categorized by fibrin content in percentage of the 
overall sample area. 
3.2.1. Immunohistochemistry H&E stain 
The thrombi of patients that were loaded with Clopidogrel showed significantly 
more often a fibrin content of over 50% in comparison to Prasugrel-pretreated 
patients as shown below in diagram 1: 
 
 
Diagram 1: 74,3% of thrombi showed a fibrin content of >50% in the Clopidogrel group. 
In the Prasugrel group 44,7% showed a fibrin content of >50%. 
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Fibrin derives from Fibrinogen and is brought into its active, insoluble form by 
thrombin. Fibrin molecules form strands which weave into a fibrin mesh. The 
mesh is then stabilized by factor XIII of the coagulation system. The entire 
aggregate of blood cells, platelets in particular and fibrin mesh turns the initially 
instable platelet plug into a solid thrombus. The two constituents interact in 
several ways at different points in time during the whole process of thrombus 
formation. Fibrinogen is one of the platelets’ GP IIb/IIIa receptor ligand and, 
early in the process, leads to adherence and activation of platelets. The 
receptor-ligand complex also acts as positive feedback loop for the signaling 
and activation pathway, thus not only amplifying the initial reaction but also 
stabilizing the entire conglomerate. Additionally, platelets, once activated, 
release several coagulation factors as well as fibrinogen, which is, as 
mentioned above, not only a ligand to the platelets’ own receptor, it is also the 
precursor of fibrin. This leads to another more indirect way of fibrin-platelet-
interaction: Thrombin, the activated factor II, is the end product of the 
coagulation cascade. On one hand it plays a vital role in fibrin mesh formation 
since it functions as protease that cleaves soluble fibrinogen in fibrin. On the 
other hand it catalyzes the entire coagulation process by recruiting and 
activating more platelets in terms of a positive feedback mechanism.  
With these findings, although presumably neither Prasugrel nor Clopidogrel acts 
directly on fibrin mesh formation, it has to be assumed that the effect of 
Prasugrel on platelet inhibition is stronger, particularly in regard to preventing 
the amplification process by positive feedback loops that are mentioned above.  
In regard to the molecular biomarkers, 3 subgroups were formed for each 
individual marker according to the level of expression: no to low expression 
meaning no or only low staining, fair or medium and high expression level.  
Diagrams below give an overview of the three expression levels in percentage 
of the overall amount of stained thrombi. The photographs show examples of 
the correspondent biomarker stained sections with none/low, medium and high 
grade of expression. In order to statistically analyze and compare the Prasugrel- 
with the Clopidogrel- loaded group, stained cells of each section were counted. 
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The only exception was made for the “platelet marker” CD42b; the areal 
staining did not permit for cells to be counted. Hence the expression grade was 
used as a powerful indicator for platelet prevalence.  
The results of the statistical analysis are presented consecutively in diagrams 
for each individual biomarker, followed by exemplary immunohistochemical 
stains of every marker and correspondent HE stain for each group: 
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3.2.2. Immunohistochemistry CD14 
CD14 expression levels: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 2: CD14 expression level in percentage of stained thrombi.  
Fig.12-14: Low, medium and strong expression level for CD14. 
Diagram 2 above demonstrates that the CD14 stained sections showed to 50% 
no or low expression of the marker. There were 40% with a medium expression 
level and 10% showed a high expression grade. 
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Diagram 3: Values are given as mean ± standard error, number of CD14 positive cells 
(Monocytes) per high power field (10x) 
When comparing the CD14 stained sections of the Prasugrel- with the 
Clopidogrel- group they showed more often a higher expression level in the 
Clopidogrel group. Although there was not a significant difference in cell count 
of CD14 stained cells this clearly signifies a trend towards the Clopidogrel 
group. CD14 is a marker expressed by monocytes and macrophages, as well 
as neutrophils. It is therefore a valuable indicator for inflammatory processes.[40]  
Especially in atherosclerosis, plaque formation, development and eventually 
plaque rupture monocytes or rather their derivatives have been found to play a 
significant role. Macrophages derive from monocytes, and in case of lipid 
accumulation within the arterial vessel walls as part of plaque formation and 
development, evolve into foam cells.[51] This process is mainly due to the 
macrophages’ scavenger function: Macrophages as part of the immune system 
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are recruited to the site of damage and take up cholesterol and lipid molecules. 
These molecules accumulate intracellular and lead to foam cell development 
with their typical lipid-rich appearance. Foam cells are suspected to play a 
crucial part in plaque rupture.[52, 53] 
The statistical trend towards the Clopidogrel group speaks therefore for an 
influence of the pretreatment agent on inflammation as well as on 
monocyte/macrophage and thus foam cell prevalence in acute or recent 
myocardial infarction. 
 
H&E and CD14 stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.15-16: Clopidogrel Loading, HE and CD14 stain 
Fig.17-18: Prasugrel Loading, HE and CD 14 stain 
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3.2.3. Immunohistochemistry CD42b 
CD42b expression levels: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 4: CD42b expression level in percentage of stained thrombi.  
Fig.19-21: Low, medium and strong expression level for CD42b. 
CD42b is a “platelet marker”. Overall, 30% of thrombi had a high expression 
grade of CD42b, an even higher amount with 50% a medium expression grade 
and a minority of 20% no to low expression. This underlines the fact that there 
is a great prevalence of platelets in coronary thrombi.  
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Diagram 5: CD42b positive area (platelets) in percentage of sample area per high 
power field (10x) 
 
Statistically, there was no significant difference in CD42b expression between 
the Clopidogrel- and the Prasugrel group as can be seen in diagram 5. The 
correspondent stains are examples for H&E as well as CD42b stained sections 
for each group. The latter also show the patchy stain patterns of this particular 
biomarker and therefore explain why the grading level was a more adequate 
tool for quantification of platelet prevalence. 
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H&E and CD42b stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.22-23: Clopidogrel Loading, HE and CD42b stain 
Fig.24-25: Prasugrel Loading, HE and CD 42b stain 
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3.2.3. Immunohistochemistry CD68 
CD68 expression levels: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 6: CD68 expression level in percentage of stained thrombi.  
Fig.26-28: Low, medium and strong expression level for CD68. 
There were no remarkable differences regarding the expression levels of CD68 
stained thrombi. Just above 35% showed low staining, just below 35% high 
staining and the rest a medium staining grade. 
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Diagram 7: Values are given as mean ± standard error, number of CD68 positive cells 
(Monocytes/Macrophages) per high power field (10x) 
 
The cell count of CD68 stained cells was with an average of >150 positive cells 
higher in the Clopidogrel group, although the difference to the Prasugrel group 
was not significant.  CD68 is a monocyte- and macrophage-specific marker. 
The findings imply that in approximately 2/3 of the stained thrombi an 
inflammatory process involving monocytes and macrophages occurred, 
regardless of the medical pretreatment. 
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H&E and CD68 stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.29-30: Clopidogrel Loading, HE and CD68 stain 
Fig. 31-32: Prasugrel Loading, HE and CD68 stain 
 
 
  
54 
 
3.2.4. Immunohistochemistry CD105 
CD105 expression levels: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 8: CD105 expression level in percentage of stained thrombi.  
Fig.33-35: Low, medium and strong expression level for CD105. 
The analysis of CD105 expression levels clearly indicates a low expression for 
this marker with over 50% of all stained sections showing no or low expression 
and only just over 10% a high expression level. 
CD105 is part of the TGFß-receptor complex and a marker primarily found in 
endothelial and smooth muscle cells, but also in monocytes and macrophages. 
It is known to play an important part in angiogenesis, which occurs in 
physiological healing processes as well as tumor growth and transformation.[43]  
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Diagram 9: Values are given as mean ± standard error, number of CD105 positive cells 
(Endothelial cells, Monocytes/Macrophages, smooth muscle cells) per high power field 
(10x) 
 
Despite the overall low expression in all thrombi, the cell count of CD105 
positive cells in the Clopidogrel group was slightly higher, although the 
difference was not significant.  
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H&E and CD105 stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.36-37: Clopidogrel Loading, HE and CD105 stain 
Fig. 38-39: Prasugrel Loading, HE and CD105 stain 
 
 
  
57 
 
3.2.5. Immunohistochemistry TGFß 
TGFß expression levels: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 10: TGFß expression level in percentage of stained thrombi.  
Fig.40-42: Low, medium and strong expression level of TGFß. 
As represented in the above diagram 10 TGFß was expressed to a medium or 
high extent, together accounting for almost 90%. Merely 12% of all stained 
sections had no or a low expression grade. Interestingly, although CD105 is 
part of the TGFß-receptor complex its expression levels were almost to the 
contrary to the TGFß-levels. 
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Diagram 11: Values are given as mean ± standard error, number of TGFß positive cells 
(platelets, monocytes/macrophages) per high power field (10x) 
 
The TGFß-receptor complex has a wide range of functions in immune response 
such as chemotaxis, proliferation, differentiation, and activation of immune cells. 
Although the multiple functions of the complex are not yet fully understood, 
TGFß is known to be secreted by monocytes/macrophages and neutrophils and 
therefore to play a role in physiological wound healing processes.  Furthermore, 
the TGFß-1 isoform is expressed in platelets. These facts make it a valid 
indicator for platelet prevalence and activity on one hand and for inflammatory 
and healing processes on the other.[43-46, 54] This is underlined by the findings 
shown above. In both groups there was a medium to high expression of TGFß 
in general, with no significant difference between the Clopidogrel and the 
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Prasugrel pretreated patients. A discretely higher prevalence was documented 
for the Clopidogrel group. 
 
 
H&E and TGFß stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 43-44: Clopidogrel Loading, HE and TGFß stain 
Fig. 45-46: Prasugrel Loading, HE and TGFß stain 
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3.2.6. Immunohistochemistry MIF 
MIF expression levels: 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 12: MIF expression level in percentage of stained thrombi.  
Fig.47-49: Low, medium and strong expression level of MIF. 
According to the statistical analysis as shown in diagram 12, 50% of all MIF-
stained thrombi had no to low, the other half medium to high expression levels 
of the marker, although it was only a minority of not only 10% that had a high 
expression of MIF. 
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Diagram 13: Values are given as mean ± standard error, number of MIF positive cells 
(monocytes/macrophages) per high power field (10x) 
 
MIF is a monocyte- and macrophage specific pro-inflammatory cytokine. It is 
responsible for monocyte adhesion and migration to the site of lesion and 
regulation of macrophage function. It is known for its involvement in 
atherosclerosis and plaque progression in CAD.[47] As indicated in diagram 13, 
there was a visible although not significant difference in the number of MIF 
positive cells between the two groups with a tendency of more positive cells in 
the Clopidgrel group.  
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H&E and MIF stains, Clopidogrel and Prasugrel: 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.50-51: Clopidogrel Loading, HE and MIF stain 
Fig.52-53: Prasugrel Loading, HE and MIF stain 
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3.2.7. Immunohistochemistry Grem1 
Gremlin1 expression levels: 
     
 
 
 
 
 
 
 
 
 
 
 
 
Diagram 14: Grem1 expression level in percentage of thrombi.  
Fig.54-56: Low, medium and strong expression level of Grem1. 
Medium and strong Grem1 expression accounted for over 2/3 of all stained 
sections, of which 46% showed a fair staining level. Low expression was 
present in 28% of all cases.  
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Diagram 15: Values are given as mean ± standard error, number of Grem1 positive 
cells (monocytes/macrophages) per high power field (10x) 
 
Grem1 in recent years has been found to be an endogenous antagonist of the 
pro-inflammatory cytokine MIF. Previous studies have shown that the blood 
plasma Grem1/MIF ratio is significantly lower in patients with ACS in contrast to 
patients with stable CAD.[48, 49] The statistical analysis as documented in 
diagram 15 clearly shows a higher amount of Grem1 positive cells in the 
Prasugrel group. Although the differences between the two groups were not 
significant, it has to be noted that the expression of MIF was higher in the 
Clopidgrel group in comparison to the Prasugrel group. Interestingly for Grem1 
the contrary is the case. This results in a lower Grem1/MIF ratio in the 
Clopidogrel group than in the Prasugrel group, suggesting that Clopidogrel 
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pretreated patients show a higher level of inflammatory processes in 
intracoronary thrombi.  
 
 
H&E and Grem1 stains, Clopidogrel and Prasugrel: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 57-58: Clopidogrel Loading, HE and Grem1 stain 
Fig. 59-60: Prasugrel Loading, HE and Grem1 stain 
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3.3. Results- Conclusion 
In summary, the most significant result of this research study is the difference in 
fibrin content of intracoronary thrombi when comparing the Clopidogrel with the 
Prasugrel pretreated group. Statistically the Clopidogrel group showed 
significantly more often a fibrin content of over 50% in comparison to the 
Prasugrel group. 
Furthermore the CD14 expression was higher in the Clopidogrel group; the 
number of CD14 positive cells signifying a trend towards the Clopidogrel group. 
The CD42b, CD68, CD105, MIF, Grem1 and TGFß stained cells did not show 
significant differences or trends between the Clopidogrel and the Prasugrel 
group although there were some interesting findings regarding the relation of 
CD105 and TGFß as well as MIF and Grem1 expression. 
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4. Discussion 
 
This study focused on Clopidogrel and Prasugrel, two of the main antiplatelet 
regimens used worldwide in patients with acute ST-elevation myocardial 
infarction undergoing PCI and their influence on architecture and composition of 
intracoronary thrombi. 
Although Prasugrel seems to have an effect on thrombus size and formation as 
suggested by Silvain, J et al. [34]  the thrombi components and morphology had 
not yet been analyzed in regard to the different pretreatment strategies that are 
in common clinical practice today.  
In this study we could demonstrate that intracoronary thrombi of patients that 
were loaded with ASA and Clopidogrel before PCI and thrombus aspiration 
showed significantly more often a fibrin content of over 50 percent as opposed 
to intracoronary thrombi of Prasugrel-loaded patients.  
This is remarkable since fibrin, together with factor XIII, is the component at the 
end of the coagulation cascade that turns the initial platelet plug into a stable, 
insoluble thrombus. This suggests that Prasugrel’s rapid onset of effect and 
more potent platelet inhibition [38] results in an overall reduced fibrin content in 
intracoronary thrombi when compared to Clopidogrel and thus makes it less 
resistant to ongoing antithrombotic treatment. The composition of thrombotic 
material of patients with acute ST-myocardial infarction has been subject to 
several research studies before.[34, 55] A significant difference in fibrin content 
had been observed, but had been correlated to time as the main impact factor 
on thrombus formation.[34] As documented in the baseline characteristics of our 
patient cohort, there was no statistically significant difference between the two 
groups regarding door-to-balloon time. Although the Clopidogrel- group’s door-
to-balloon time was overall longer, it also has to be taken into account that the 
onset of action for Clopidogrel ranges from 2 to 6 hours, whereas Prasugrel 
starts taking effect after 30 minutes.[37] Therefore, in order to be able to 
correlate the effect of the two antithrombotic agents to our findings and to 
compare the two groups with each other we selected patients that were treated 
and the thrombotic material obtained within 24 hours (acute myocardial 
infarction, majority of patient cohort) or between 24-72 hours (recent myocardial 
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infarction). Our study therefore differs from the previous one by Silvain et al. 
primarily in its objective to compare two P2Y12-inhibitors regarding their impact 
on thrombus architecture, an extended time span and the methods used. In 
respect of our aim to investigate the differences between Clopidogrel and 
Prasugrel treated patients the time frame had to be adjusted due to the 
difference in pharmacodynamics and –kinetics. With this premise, we 
established a basis where time can only be factored in if related to the P2Y12-
inhibitor that was being analyzed, leading to valid, unbiased results. 
 
In our study we could furthermore show that there is a statistical trend of CD14 
positive cells towards the Clopidogrel group. CD14 is a monocyte/macrophage 
marker. Although it is to a lesser extent also expressed by neutrophils, it has 
lipopolysaccharide-receptor functions [51,56], a crucial feature for lipid-uptake and 
thus for the transformation of macrophages into foam cells. Since foam cells are 
known to play an important role in atherosclerosis, plaque formation and 
rupture, a higher prevalence of CD14 positive cells implies a higher incidence of 
these and similar pro-inflammatory processes in the Clopidogrel group. CD14 
has so far mainly been investigated in atherosclerotic plaques of the carotids.[56, 
57] In the study by Hermansson et al. it was not only shown that CD14 is 
expressed in thrombotic carotid lesions but also that the receptor was 
suppressed in macrophages by angiotensin receptor blockers. It has been 
furthermore suggested that angiotensin receptor blockers have anti-
inflammatory effects on patients with atherosclerotic lesions like the ones 
studied by Hermansson et al.  
According to the baseline characteristics of our study population only 17% of 
the entire patient cohort had an ARB in their concomitant medication, 18.5% in 
the Clopidogrel and 16.3% in the Prasugrel group. The similar percentage is 
favorable in order to be able to compare the two treatment arms. The trend 
towards the Clopidogrel group therefore signifies that CD14 expression and 
therefore inflammation, lipid-uptake and foam cell formation are higher in the 
Clopidgrel group. In regard to Hermansson’s study and the observed results of 
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our analysis of intracoronary thrombi a routine combination of Clopidogrel and 
ARBs might be considered. 
CD42 as a platelet marker was selected to be used in immunohistochemical 
stainings since platelets and fibrin are the main constituents of arterial thrombi 
as had been shown before.[1, 34] Again, Silvain et al. could show that there is a 
proportional shift towards the amount of fibrin at the expense of the amount of 
platelets in correlation to time. In regard to the different antiplatelet regimens 
compared in our study and platelet prevalence there was no significant 
difference between the two groups. It is noteworthy that platelet prevalence is 
not affected by either Clopidogrel or Prasugrel. In fact a similar prevalence of 
platelets implies a valid comparability between the two pretreatment arms. In 
order to additionally investigate the effects of the two drugs on platelets’ activity 
and function corresponding studies such as f.ex. blood plasma multiplate testing 
would be useful.   
The monocyte/macrophage specific marker CD68 is known and has been 
commonly used as an indicator for inflammatory processes. In our study CD68 
was expressed to similar amounts in both pretreatment arms. The statistical 
results therefore suggest that inflammation is equally high in both groups. 
Fukijkschot WW et al. have previously shown that CD68 is more strongly 
expressed in lytic coronary thrombi than in fresh or organized ones implying a 
correlation to thrombus age.[42] Based on this finding, it can be claimed that 
thrombus age did not differ significantly between the two groups in our study. 
Fukijkschot WW et al. also found a significant positive correlation between 
patient’s age and the prevalence of CD68 and thus inflammation in 
intracoronary thrombi. Interestingly, in our patient cohort there was a statistically 
significant age difference between the two groups, with the Clopidogrel group’s 
average patient age being higher. This is in accordance with the, although not 
significantly, higher maximum CRP plasma levels as well as the higher 
expression of CD68. Further investigation especially regarding differences in 
genetic expression, as has exemplary been conducted for soluble CD14 by 
Reiner et al. [58], and correlation to age between the two groups would elucidate 
these tendencies.  
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TGFß was highly expressed in both groups, as opposed to CD105 which forms 
part of the TGFß receptor complex. CD105 in its soluble form has been shown 
to be decreased in serum of patients with CAD.[59] Saita et al. found a positive 
correlation between the degree of CAD and a stepwise decrease of Endoglin 
serum levels with the severity of the disease. In line with these findings Li et al. 
had also shown that serum levels of CD105 and TGFß1 are decreased in 
patients with CAD, the amount of CD105/TGFß1 receptor complex though was 
increased as a probable reason for the decrease of the single complex 
constituents.[60] Although part of the same complex it has to be mentioned that 
CD105 is known for playing a part in neovascularization in tumors and 
atherosclerotic plaques [61] , whereas TGFß plays a significant role in platelet 
activation and wound healing. There are also preliminary studies suggesting a 
genetic component in TGFß expression.[54]  
In our study we could show that the expression of TGFß is generally high in all 
patients with acute or recent myocardial infarction suggesting a high level of 
platelet activation whereas CD105 expression is rather low in all intracoronary 
thrombi with no significant difference between the Clopidogrel and the Prasugrel 
group. 
MIF, being an inflammatory cytokine has been used in this study to compare 
and detect potential differences in inflammation present in intracoronary thrombi 
between the two antithrombotic treatment arms. The MIF prevalence was 
statistically higher, although not significantly in the Clopidogrel group, 
suggestive for a higher amount of inflammation and macrophage activity in this 
group in accordance with the results of CD68 expression. Grem1 is known to be 
an endogenous antagonist of MIF. Its expression levels were higher in the 
Prasugrel group. In a previous study where we compared MIF and Grem1 blood 
plasma levels we could show that the Grem1/MIF ratio was significantly lower in 
a cohort of ACS patients in contrast to patients with stable.[48] The current study 
shows that the Grem1/MIF ratio is although not significantly but nonetheless 
notably lower in the Clopidogrel group. This again suggests a higher level of 
inflammation in the Clopidogrel group.  
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In summary we could show in our study that the antithrombotic pretreatment 
has an impact of thrombus composition and architecture, although not all 
underlying factors are completely understood. 
Further investigations in regard to time, age and genetics of a larger patient 
cohort and the potential influences of these factors especially on inflammatory 
processes represented in intracoronary thrombi would be useful to elucidate our 
findings and to find more individualized treatment strategies of patients with 
acute or recent myocardial infarction. 
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5. Summary 
With the rapid progress of CAD artery disease becoming the leading cause of 
mortality and morbidity worldwide a thorough understanding and constant 
improvement of treatment strategies of the underlying causes has become an 
ongoing task for researchers and clinicians around the globe.  
The standard treatment for patients undergoing PCI is currently a dual 
antiaggregatory therapy with ASA and another antiplatelet drug either of the 
thienopyridine group (Clopidogrel, Prasugrel, Ticlopidine) or with a non-
thienopyridine derivative such as Ticagrelor or Cangrelor. In this research study 
we focused on the two main representatives of the thienopyridine group, 
Clopidogrel and Prasugrel. 
It has been demonstrated before that Prasugrel shows more stable 
pharmacokinetics and –dynamics, an overall more potent platelet inhibition and 
a more rapid onset of effect.[38] 
Based on the hypothesis that Prasugrel in comparison to Clopidogrel not only 
reduces intracoronary thrombus size but also affects its composition and thus 
its architecture due to its beneficial effects mentioned above, the aim of this 
research study was to analyze and compare those features of intracoronary 
thrombi of a cohort of STEMI – patients. 
For the analysis, a total of 102 patients from 2 cardiological centers underwent 
PCI and thrombectomy. 51 of the entire cohort received Clopidogrel, the other 
half Prasugrel pretreatment either in the ambulance or on hospital admission 
with loading doses of ASA 500 mg + Clopidogrel 600 mg or ASA 500 mg + 60 
mg Prasugrel according to standard clinical practice. The aspirated thrombi of 
those two groups were consecutively analyzed further by histological staining. 
In order to gain a differentiated overview of the thrombi composition the 
sections were stained using a variety of molecular biomarkers (CD14, CD42b, 
CD68, CD105, MIF, Grem1, TGFß) besides the standard H&E stain. The 
obtained results were then compared between the two groups and related to 
clinical findings and patients’ characteristics. 
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The most significant result was the difference in fibrin content between the two 
groups. The intracoronary thrombi of patients preloaded with Clopidogrel 
showed significantly more often a fibrin content of over 50% of the sampled 
area in comparison to the Prasugrel group. Regarding the clinical parameters, 
risk factors and other patients’ characteristics there were no significant 
differences between the two groups so that these parameters can be excluded 
as potential influencing factors. We could also show a trend towards CD14 
prevalence in the Clopidogrel group. Although not significantly different, this 
speaks for an augmented inflammatory reaction with a higher involvement of 
monocytes and macrophages in the Clopidogrel group. The other biomarkers 
did not differ significantly in terms of expression between the two treatment 
arms.  
We could therefore show that the type of antithrombotic pretreatment with 
Prasugrel or Clopidogrel has a direct impact on thrombus composition and thus 
architecture and that there is a causal relationship between Prasugrel 
pretreatment and reduced fibrin content in intracoronary thrombi of patients with 
STEMI. 
Further investigation of these effects in a larger patient cohort also in 
consideration of the individual’s predisposition, such as protein and gene 
expression and additional research regarding different antiplatelet regimens 
might help us to further understand the underlying pathophysiological processes 
and thus, develop new, possibly more individualized, treatment strategies for 
patients with ACS. 
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7. Deutsche Zusammenfassung 
Mit dem raschen Aufsteigen der Koronaren Herzerkrankung zur Hauptursache 
für Mortalität und Morbidität weltweit ist ein tiefgreifendes Verstehen und 
kontinuierliche Verbesserung der Therapiestrategien der zugrundliegenden 
Ursachen zur Voraussetzung und fortwährenden Aufgabe für Forscher und 
Kliniker auf der ganzen Welt geworden. 
Die aktuelle Standardbehandlung für Patienten vor oder nach PCI ist eine duale 
antiaggregatorische Therapie mit ASS und einem 
Thrombozytenaggregationshemmer entweder aus der Thienopyridin-Gruppe 
(Clopidogrel, Prasugrel, Ticlopidin) oder mit einem nicht-Thienopyridin Derivat 
wie Ticagrelor oder Cangrelor. In dieser Studie wurde der Fokus auf die zwei 
Hauptrepräsentanten der Thienopyridin-Gruppe, Clopidogrel und Prasugrel 
gelegt. 
Es ist bereits zuvor demonstriert worden, dass Prasugrel sowohl über eine 
stabilere Pharmakokinetik und –dynamik verfügt, als auch eine potentere 
Plättchenhemmung und einen rascheren Effektbeginn aufweist.[38] 
Basierend auf der Hypothese dass Prasugrel im Vergleich zu Clopidogrel nicht 
nur die Größe intrakoronarer Thromben reduziert, sondern aufgrund der oben 
beschriebenen vorteilhaften Effekte auch ihre Komposition und somit die 
Thrombusarchitektur beeinflusst,  war das Ziel dieser Studie diese 
Charakteristiken von intrakoronaren Thromben in einer Kohorte von STEMI-
Patienten zu analysieren und zu vergleichen.  
Für die Studie wurden insgesamt 102 Patienten aus 2 kardiologischen Zentren, 
die sich einer PCI und Thrombektomie unterzogen, rekrutiert. 51 Patienten 
dieser Kohorte erhielten ein Clopidogrel-, die andere Hälfte ein Prasugrel- 
Loading entweder im Rettungswagen oder bei Krankenhausaufnahme. Die 
Loading-Dosis war ASS 500 mg +  Clopidogrel 600 mg oder ASS 500 mg + 
Prasugrel 60 mg entsprechend Standardklinikroutine. Die aspirierten Thromben 
dieser zwei Gruppen wurden im Anschluss mittels Immunhistologie weiter 
untersucht.   
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Um einen differenzierten Überblick über die Thrombenkomposition zu erhalten, 
wurden die histologischen Schnitte neben der Standard HE-Färbung mit einer 
Auswahl an molekularen Biomarkern (CD14, CD42b, CD68, CD105, MIF, 
Grem1, TGFß) gefärbt. Die Ergebnisse wurden dann zwischen den zwei 
Gruppen verglichen und in Relation zu den klinischen Befunden und Patienten-
Charakteristika gesetzt. 
Der größte signifikante Unterschied zwischen den zwei Gruppen zeigte sich 
hinsichtlich des Fibringehalts. Die intrakoronaren Thromben der Patienten, die 
mit Clopidogrel behandelt worden waren zeigten häufiger einen Fibrinanteil von 
über 50% der ausgewerteten Region im Vergleich zur Prasugrel Gruppe. 
Angesichts der klinischen Parameter, Risikofaktoren und weiteren 
Patientenmerkmale zeigten sich keine wesentlichen Unterschiede zwischen den 
zwei Gruppen, sodass diese Parameter als potenzielle Einflussfaktoren 
ausgeschlossen werden können. 
Wir konnten auch einen Trend zu einer erhöhten CD14 Prävalenz in der 
Clopidogrel Gruppe aufweisen. Wenn auch nicht signifikant erhöht, so spricht 
dieser Trend doch für eine gesteigerte inflammatorische Reaktion mit erhöhter 
Beteiligung von Monozyten und Makrophagen in der Clopidogrel-Gruppe. Die 
übrigen Biomarker zeigten keine signifikanten Unterschiede zwischen den zwei 
Behandlungsarmen in Bezug auf ihre Expression. 
Somit konnten wir zeigen, dass die Art der antithrombozytären Behandlung mit 
Prasugrel oder Clopidogrel einen direkten Einfluss auf die 
Thrombuskomposition und damit –architektur hat und dass ein 
Kausalzusammenhang zwischen Prasugrel-Loading und geringerem 
Fibringehalt in intrakoronaren Thromben von STEMI-Patienten besteht. 
Weitere Untersuchungen dieser Effekte in einer größeren Patientenkohorte, 
auch unter Berücksichtigung der individuellen Prädisposition, wie 
beispielsweise Protein- und Genexpression und zusätzliche Studien in Hinsicht 
auf andere antithrombozytäre Therapien könnten uns helfen die zugrunde 
liegenden pathophysiologischen Prozesse besser zu verstehen und so neue, 
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möglicherweise individualisiertere Behandlungsstrategien für Patienten mit ACS 
zu entwickeln. 
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